Defibrotide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Defibrotide
- Pharmacist Assessment Report
- Defibrotide: Endothelial-protective, profibrinolytic oligonucleotide → pseudo-von Willebrand disease
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Defibrotide: Endothelial-protective, profibrinolytic oligonucleotide → pseudo-von Willebrand disease
One-Sentence Summary
Defibrotide is an endothelial-protective, profibrinolytic oligonucleotide mixture marketed in Canada under a single licence. The TxGNN model predicts it may be effective for pseudo-von Willebrand disease, but no clinical trials and no publications currently support this direction, so the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | pseudo-von Willebrand disease |
| TxGNN Prediction Score | 0.9991 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Defibrotide is generally described as an endothelial-protective agent that reduces endothelial activation and prothrombotic signalling and enhances fibrinolysis.
Pseudo-von Willebrand disease (platelet-type von Willebrand disease) is a bleeding disorder caused by a gain-of-function change in platelet glycoprotein Ib-alpha. A mechanistic link between defibrotide and this platelet receptor abnormality is not supported by the available data. The high model score is therefore a computational signal only.
There is also a safety concern. Defibrotide has antithrombotic and profibrinolytic activity, and using it in a patient with a bleeding disorder could plausibly worsen bleeding.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02465981 | DEFITELIO | Not recorded | Not recorded |
Safety Considerations
- Drug Interactions: 100 interacting drugs were identified in the interaction screening; examples of those rated Major include:
- Acetylsalicylic acid
- Deferasirox
- Abciximab
- Acalabrutinib
- Fondaparinux
- Alteplase
- Anagrelide
- Ibritumomab tiuxetan
- Tositumomab
Moderate-rated examples include ibuprofen, ketorolac, celecoxib, fluvoxamine, omega-3 fatty acids, fenfluramine, dexfenfluramine and sibutramine. Many of these are agents that affect platelets or coagulation, which is relevant to a bleeding disorder.
- Bleeding risk: Given its antithrombotic and fibrinolytic activity, defibrotide is a concern in any disease that is already hemorrhagic. Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature, no plausible mechanistic link to the platelet receptor defect in this disease has been identified, and the drug’s bleeding-related pharmacology raises a safety concern. The evidence level is L5 (model prediction only).
To proceed, the following is needed:
- Mechanistic data showing a plausible link between defibrotide and the platelet glycoprotein Ib-alpha abnormality
- Package insert warnings and contraindications from Health Canada
- Detailed mechanism of action data
- Any preclinical or clinical study directly addressing this disease
- A bleeding-risk assessment before any consideration of use in this population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.